ID   Rh30
AC   CVCL_0041
AS   CVCL_1696; CVCL_UF98
SY   RH30; RH-30; Rh-30; RH30SJ; SJRH-30; SJRH30; SJ-RH30; SJ-Rh 30; SJRH 30; SJCRH30; RC13; RMS-13; RMS 13; RMS13
DR   BTO; BTO:0005379
DR   CLO; CLO_0009030
DR   CLO; CLO_0037074
DR   CLO; CLO_0037076
DR   EFO; EFO_0002329
DR   EFO; EFO_0005722
DR   4DN; 4DNSR3QR626J
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2061
DR   BCRC; 60420
DR   BCRJ; 0344
DR   BioGRID_ORCS_Cell_line; 479
DR   BioSample; SAMN03471424
DR   BioSample; SAMN03473112
DR   BioSample; SAMN03473563
DR   BioSample; SAMN10987899
DR   BioSample; SAMN10988045
DR   cancercelllines; CVCL_0041
DR   Cell_Model_Passport; SIDM01095
DR   ChEMBL-Cells; CHEMBL3308364
DR   ChEMBL-Targets; CHEMBL1075575
DR   Cosmic; 687957
DR   Cosmic; 687964
DR   Cosmic; 801758
DR   Cosmic; 909716
DR   Cosmic; 1037297
DR   Cosmic; 1048110
DR   Cosmic; 1097749
DR   Cosmic; 1082515
DR   Cosmic; 1104562
DR   Cosmic; 1108737
DR   Cosmic; 1309335
DR   Cosmic; 1509197
DR   Cosmic; 1620038
DR   Cosmic; 1718361
DR   Cosmic; 2355914
DR   Cosmic; 2820087
DR   Cosmic-CLP; 909716
DR   DepMap; ACH-000833
DR   DepMap; ACH-001189
DR   DepMap; ACH-001741
DR   DSMZ; ACC-489
DR   DSMZCellDive; ACC-489
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS504BIZ
DR   ENCODE; ENCBS516AAA
DR   ENCODE; ENCBS517AAA
DR   GDSC; 909716
DR   GEO; GSM186449
DR   GEO; GSM186450
DR   GEO; GSM186451
DR   GEO; GSM186452
DR   GEO; GSM219757
DR   GEO; GSM887573
DR   GEO; GSM888620
DR   GEO; GSM888656
DR   GEO; GSM1670425
DR   GEO; GSM1676311
DR   GEO; GSM1676315
DR   GEO; GSM1701645
DR   GEO; GSM1701649
DR   IARC_TP53; 356
DR   IARC_TP53; 24983
DR   IARC_TP53; 27704
DR   IGRhCellID; SJRH30
DR   LiGeA; CCLE_004
DR   LINCS_HMS; 50041
DR   LINCS_LDP; LCL-1408
DR   LINCS_LDP; LCL-1414
DR   PharmacoDB; RH30_1312_2019
DR   PRIDE; PXD007755
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0041
DR   PubChem_Cell_line; CVCL_0041
DR   Wikidata; Q54950341
RX   PubMed=2766305;
RX   PubMed=3691179;
RX   PubMed=7536457;
RX   PubMed=8275086;
RX   PubMed=8383879;
RX   PubMed=8617485;
RX   PubMed=9802058;
RX   PubMed=11051265;
RX   PubMed=17354236;
RX   PubMed=17471488;
RX   PubMed=19147553;
RX   PubMed=19235922;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20922763;
RX   PubMed=21948088;
RX   PubMed=22142829;
RX   PubMed=22460905;
RX   PubMed=23578105;
RX   PubMed=23665679;
RX   PubMed=23828214;
RX   PubMed=23882450;
RX   PubMed=25485619;
RX   PubMed=25749379;
RX   PubMed=25806826;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31448612;
RX   PubMed=31978347;
RX   PubMed=32758582;
RX   PubMed=35760101;
RX   PubMed=35839778;
WW   https://www.cccells.org/PDF_Files/Rhabdomyosarcoma/Rh30%20Cell%20Line%20Data%20Sheet.pdf
WW   http://www.cccells.org/cellreqs-ncipptp.php
WW   https://www.proteinatlas.org/learn/cellines
WW   http://www.pptpinvitro.org/cell_lines_panel.php
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 37 hours (PubMed=20922763); 35.5 +- 3.6 hours (PubMed=35760101); ~35 hours (DSMZ=ACC-489); 35 hours (COG).
CC   HLA typing: A*11:17,24:08; B*35:01,35:01; C*18:01,18:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086; PubMed=17471488; PubMed=23578105; PubMed=25485619; PubMed=25806826).
CC   Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=9802058; PubMed=19147553; PubMed=25749379; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.64%; Native American=0.36%; East Asian, North=1.57%; East Asian, South=0.14%; South Asian=4.15%; European, North=49.28%; European, South=41.87% (PubMed=30894373).
CC   Discontinued: DepMap; ACH-001741; true.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; COG; Cosmic-CLP; DepMap; DSMZ; Genomics_Center_BCF_Technion; PubMed=20922763; PubMed=21948088; PubMed=25877200
ST   Amelogenin: X (COG)
ST   Amelogenin: X,Y (ATCC; Cosmic-CLP; DepMap; DSMZ; Genomics_Center_BCF_Technion; PubMed=20922763; PubMed=21948088; PubMed=25877200)
ST   CSF1PO: 10,11
ST   D10S1248: 12
ST   D12S391: 20
ST   D13S317: 10,11 (PubMed=21948088)
ST   D13S317: 11 (COG; DepMap; DSMZ; Genomics_Center_BCF_Technion; PubMed=20922763; PubMed=25877200)
ST   D16S539: 12
ST   D18S51: 15,16
ST   D19S433: 14,15.2 (COG; Genomics_Center_BCF_Technion; PubMed=20922763)
ST   D19S433: 14,16 (DSMZ)
ST   D1S1656: 12,16
ST   D21S11: 29,31.2 (COG; DepMap; DSMZ; Genomics_Center_BCF_Technion; PubMed=20922763)
ST   D21S11: 31.2 (PubMed=25877200)
ST   D22S1045: 16,17
ST   D2S1338: 17,20
ST   D2S441: 11,14
ST   D3S1358: 15
ST   D5S818: 12,13 (ATCC; COG; Cosmic-CLP; DepMap; Genomics_Center_BCF_Technion; PubMed=20922763; PubMed=21948088; PubMed=25877200)
ST   D5S818: 12,13,14 (DSMZ)
ST   D7S820: 10
ST   D8S1179: 12,15
ST   FGA: 22
ST   Penta D: 11 (PubMed=25877200)
ST   Penta D: 11,12 (DepMap; DSMZ; Genomics_Center_BCF_Technion)
ST   Penta E: 7 (PubMed=25877200)
ST   Penta E: 7,17 (DepMap; DSMZ; Genomics_Center_BCF_Technion)
ST   TH01: 9,9.3
ST   TPOX: 8,11 (ATCC; COG; Cosmic-CLP; DepMap; DSMZ; Genomics_Center_BCF_Technion; PubMed=20922763; PubMed=21948088)
ST   TPOX: 11 (PubMed=25877200)
ST   vWA: 17,18
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   17Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   PubMed=2766305;
RA   Roberts W.M., Douglass E.C., Peiper S.C., Houghton P.J., Look A.T.;
RT   "Amplification of the gli gene in childhood sarcomas.";
RL   Cancer Res. 49:5407-5413(1989).
//
RX   PubMed=3691179; DOI=10.1159/000132446;
RA   Douglass E.C., Valentine M., Etcubanas E., Parham D.M., Webber B.L.,
RA   Houghton P.J., Houghton J.A., Green A.A.;
RT   "A specific chromosomal abnormality in rhabdomyosarcoma.";
RL   Cytogenet. Cell Genet. 45:148-155(1987).
//
RX   PubMed=7536457; DOI=10.1002/gcc.2870120305;
RA   Biegel J.A., Nycum L.M., Valentine V., Barr F.G., Shapiro D.N.;
RT   "Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar
RT   rhabdomyosarcoma by fluorescence in situ hybridization.";
RL   Genes Chromosomes Cancer 12:186-192(1995).
//
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
//
RX   PubMed=8383879; DOI=10.1126/science.8383879;
RA   Tapscott S.J., Thayer M.J., Weintraub H.M.;
RT   "Deficiency in rhabdomyosarcomas of a factor required for MyoD
RT   activity and myogenesis.";
RL   Science 259:1450-1453(1993).
//
RX   PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X;
RA   Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D.,
RA   Lollini P.-L., Picci P., Bertoni F., Baldini N.;
RT   "Immunostaining of the p30/32MIC2 antigen and molecular detection of
RT   EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral
RT   neuroectodermal tumor.";
RL   Hum. Pathol. 27:408-416(1996).
//
RX   PubMed=9802058;
RA   McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A.,
RA   Harris L.C.;
RT   "Bax is an important determinant of chemosensitivity in pediatric
RT   tumor cell lines independent of Bcl-2 expression and p53 status.";
RL   Oncol. Res. 10:235-244(1998).
//
RX   PubMed=11051265;
RA   Petak I., Douglas L., Tillman D.M., Vernes R., Houghton J.A.;
RT   "Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced
RT   apoptosis and highly sensitive to TRAIL-induced apoptosis.";
RL   Clin. Cancer Res. 6:4119-4127(2000).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=17471488; DOI=10.1002/path.2170;
RA   Lae M., Ahn E.H., Mercado G.E., Chuai S., Edgar M., Pawel B.R.,
RA   Olshen A., Barr F.G., Ladanyi M.;
RT   "Global gene expression profiling of PAX-FKHR fusion-positive alveolar
RT   and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.";
RL   J. Pathol. 212:143-151(2007).
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=19235922; DOI=10.1002/gcc.20655;
RA   Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C.,
RA   Koster J., Summersgill B.M., Messahel B., Versteeg R.,
RA   Pritchard-Jones K., Kool M., Shipley J.M.;
RT   "Genomic imbalances in rhabdomyosarcoma cell lines affect expression
RT   of genes frequently altered in primary tumors: an approach to identify
RT   candidate genes involved in tumor development.";
RL   Genes Chromosomes Cancer 48:455-467(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004;
RA   Belyea B.C., Naini S., Bentley R.C., Linardic C.M.;
RT   "Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma
RT   tumorigenesis.";
RL   Clin. Cancer Res. 17:7324-7336(2011).
//
RX   PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056;
RA   Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A.,
RA   Borsu L., Barr F.G., Ladanyi M.;
RT   "Oncogene mutation profiling of pediatric solid tumors reveals
RT   significant subsets of embryonal rhabdomyosarcoma and neuroblastoma
RT   with mutated genes in growth signaling pathways.";
RL   Clin. Cancer Res. 18:748-757(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23578105; DOI=10.1111/cas.12173;
RA   Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R.,
RA   Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y.,
RA   Ogawa S.;
RT   "Characterization of genetic lesions in rhabdomyosarcoma using a
RT   high-density single nucleotide polymorphism array.";
RL   Cancer Sci. 104:856-864(2013).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23828214; DOI=10.3892/or.2013.2588;
RA   Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y.,
RA   Kitagawa Y., Morikawa Y., Kuroda T.;
RT   "Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with
RT   EGFR amplification in vitro.";
RL   Oncol. Rep. 30:1081-1086(2013).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25749379; DOI=10.18632/oncotarget.2889;
RA   Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T.,
RA   Cinatl J. Jr.;
RT   "Enzastaurin inhibits ABCB1-mediated drug efflux independently of
RT   effects on protein kinase C signalling and the cellular p53 status.";
RL   Oncotarget 6:17605-17620(2015).
//
RX   PubMed=25806826; DOI=10.1371/journal.pone.0121474;
RA   Schmitt-Ney M., Camussi G.;
RT   "The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes
RT   with normal FOXO activity and the TGF-beta pathway.";
RL   PLoS ONE 10:E0121474-E0121474(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31448612; DOI=10.1021/acs.jproteome.9b00157;
RA   Rammal G., Fahs A., Kobeissy F., Mechref Y., Zhao J.-F., Zhu R.,
RA   Diab-Assaf M., Saab R., Ghayad S.E.;
RT   "Proteomic profiling of rhabdomyosarcoma-derived exosomes yield
RT   insights into their functional role in paracrine signaling.";
RL   J. Proteome Res. 18:3567-3579(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32758582; DOI=10.1016/j.gene.2020.145025;
RA   Batchu S., Kellish A.S., Hakim A.A.;
RT   "Assessing alveolar rhabdomyosarcoma cell lines as tumor models by
RT   comparison of mRNA expression profiles.";
RL   Gene 760:145025.1-145025.5(2020).
//
RX   PubMed=35760101; DOI=10.1016/j.jbc.2022.102196;
RA   Rahman M.M., Young C.K.J., Goffart S., Pohjoismaki J.L.O., Young M.J.;
RT   "Heterozygous p.Y955C mutation in DNA polymerase gamma leads to
RT   alterations in bioenergetics, complex I subunit expression, and mtDNA
RT   replication.";
RL   J. Biol. Chem. 298:102196.1-102196.29(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//